4//SEC Filing
Simon Farrell 4
Accession 0000950170-25-037880
CIK 0001563880other
Filed
Mar 11, 8:00 PM ET
Accepted
Mar 12, 4:00 PM ET
Size
21.7 KB
Accession
0000950170-25-037880
Insider Transaction Report
Form 4
Simon Farrell
Chief Commercial Officer
Transactions
- Exercise/Conversion
Performance Stock Option (right to buy)
2025-03-10−17,500→ 0 totalExercise: $3.21Exp: 2031-02-16→ Common Stock (17,500 underlying) - Exercise/Conversion
Common Stock
2025-03-10$3.91/sh+63,813$249,509→ 126,963 total - Sale
Common Stock
2025-03-10$6.73/sh−76,963$517,776→ 81,250 total - Award
Performance Stock Option (right to buy)
2025-03-10+38,400→ 38,400 totalExercise: $2.38From: 2025-03-10Exp: 2034-02-14→ Common Stock (38,400 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-03-10−31,250→ 18,750 totalExercise: $0.51Exp: 2032-02-10→ Common Stock (31,250 underlying) - Exercise/Conversion
Common Stock
2025-03-10$3.21/sh+17,500$56,175→ 63,150 total - Exercise/Conversion
Common Stock
2025-03-10$0.51/sh+31,250$15,969→ 158,213 total - Sale
Common Stock
2025-03-10$7.15/sh−4,350$31,102→ 76,900 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-10−63,813→ 11,187 totalExercise: $3.91Exp: 2030-09-22→ Common Stock (63,813 underlying)
Footnotes (8)
- [F1]This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.
- [F6]Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.
- [F7]This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.
- [F8]This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
Related Parties
1- filerCIK 0001965585
Filing Metadata
- Form type
- 4
- Filed
- Mar 11, 8:00 PM ET
- Accepted
- Mar 12, 4:00 PM ET
- Size
- 21.7 KB